menu
    • menu

    Company profile for Amarin

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AmarinIreland Flag
    Country
    Country
    Ireland
    Address
    Address
    Spaces South Docklands Block C 77 Sir John Rogerson's Quay Dublin 2, D02 Vk60
    Telephone
    Telephone
    1-855-827-2372
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://amarincorp.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/amarin-corporation
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Bio-Europe Spring

    Bio-Europe Spring

    Not Confirmed

    envelop Contact Supplier

    Bio-Europe Spring

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amarin Emphasizes Icosapent Ethyl's Role In Cardiovascular Risk
    Amarin Emphasizes Icosapent Ethyl's Role In Cardiovascular Risk

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258171/18362/en/Amarin-Highlights-Guideline-Recommended-Role-of-Icosapent-Ethyl-in-Managing-Cardiovascular-Risk-Following-Release-of-Updated-2026-ACC-AHA-Multisociety-Dyslipidemia-Guideline.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    REDUCE-IT Data on EPA Effects to Be Presented at ACC Expo
    REDUCE-IT Data on EPA Effects to Be Presented at ACC Expo

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256251/18362/en/New-REDUCE-IT-Data-in-Patients-at-Extreme-Cardiovascular-Risk-and-In-Vitro-Research-on-the-Mechanistic-Effects-of-Eicosapentaenoic-Acid-EPA-on-Lipoprotein-a-Lp-a-Oxidation-to-be-Pr.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Icosapent Ethyl Reduces Hospitalization And Death Risk
    Icosapent Ethyl Reduces Hospitalization And Death Risk

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247357/18362/en/Effects-of-Icosapent-Ethyl-on-Risk-and-Duration-of-Hospitalizations-and-Death-in-REDUCE-IT-Post-Hoc-Analysis-Published-in-the-European-Journal-of-Preventive-Cardiology.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case

    27 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/scotus-weighs-skinny-labels-top-us-lawyer-calls-toss-amarin-case-over-hikmas-vascepa-generic

    FIERCE PHARMA
    27 Feb 2026
    Share Share
    Amarin Unveils 2025 Q4 And Full-Year Financials
    Amarin Unveils 2025 Q4 And Full-Year Financials

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244479/18362/en/Amarin-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Amarin Spotlights Underused CVD Therapies for American Heart
    Amarin Spotlights Underused CVD Therapies for American Heart

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242553/18362/en/This-American-Heart-Month-Amarin-Spotlights-the-Need-to-Prioritize-Proven-Widely-Available-Yet-Underutilized-Therapies-in-the-Battle-Against-Cardiovascular-Disease.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search